长非编码RNA ZEB1-AS1在乳腺癌中的表达及其临床意义  

Expression and clinic significance of long non-coding RNA ZEB1-AS1 in breast cancer

作　　者：王妮娜[1] 李晓花[1] 陈敏丽 朱勇[1] Wang Nina;Li Xiaohua;Chen Minli;Zhu Yong(Department of Radiotherapy, Baoji Central Hospital of Shaanxi Province, Baoji 721008, China)

机构地区：[1]陕西省宝鸡市中心医院放射治疗科,721008

出　　处：《国际肿瘤学杂志》2019年第4期199-204,共6页Journal of International Oncology

摘　　要：目的探讨长非编码RNA ZEB1-AS1在乳腺癌中的表达及其临床意义。方法选取2007年6月至2015年4月陕西省宝鸡市中心医院的130例乳腺癌患者。采用实时荧光定量PCR(qRT-PCR)检测乳腺癌组织及对应癌旁正常组织中ZEB1-AS1的表达量;分析ZEB1-AS1表达量与乳腺癌患者临床特征、生存期之间的关系。通过siRNA技术干扰ZEB1-AS1的表达,采用CCK-8实验、克隆形成实验、Transwell实验检测对照组、siRNA-1组、siRNA-2组乳腺癌细胞株MCF-7的增殖能力、克隆形成能力、迁移能力。结果ZEB1-AS1在乳腺癌组织中表达量高于对应癌旁正常组织[M(QR):0.001 6(0.005 1)∶0.000 9(0.001 5);Z=-4.426,P<0.001]。ZEB1-AS1高表达与乳腺癌患者淋巴结转移(χ2=9.148,P=0.027)、人表皮生长因子受体2阴性(χ2=5.039,P=0.025)及三阴性乳腺癌(χ2=4.597,P=0.032)相关。ZEB1-AS1高表达患者较低表达患者生存期缩短(χ2=14.340,P<0.001)。细胞增殖实验结果显示,ZEB1-AS1敲低后72 h,对照组、siRNA-1组、siRNA-2组细胞吸光度值分别为0.605±0.049、0.488±0.054、0.417±0.038,3组间差异有统计学意义(F=15.936,P<0.001),2个干扰组细胞增殖能力均明显较对照组减弱(均P<0.05)。对照组、siRNA-1组、siRNA-2组的细胞克隆数分别为297.5±11.4、192.0±12.1、204.8±12.8,3组间差异具有统计学意义(F=112.526,P<0.001),2个干扰组细胞克隆形成能力均明显较对照组降低(均P<0.001)。对照组、siRNA-1组、siRNA-2组的迁移细胞数分别为184.5±8.6、147.5±18.6、57.6±7.3,3组间差异具有统计学意义(F=12.409,P=0.001),2个干扰组细胞迁移能力均明显较对照组降低(均P<0.001)。结论ZEB1-AS1在乳腺癌中高表达,且高表达将缩短乳腺癌患者生存期,干扰ZEB1-AS1能够抑制乳腺癌细胞增殖、迁移和克隆形成能力。Objective To detect the expression and clinic significance of long non-coding RNA ZEB1-AS1 in breast cancer. Methods A total of 130 patients with breast cancer in Baoji Central Hospital of Shaanxi Province from June 2007 to April 2015 were selected. Quantitative real-time PCR (qRT-PCR) was used to detect the expression level of ZEB1-AS1 in breast cancer tissues and corresponding normal tissues, and the relationships between the expression level of ZEB1-AS1 and the clinic characteristics of the patients and their overall survival time were analyzed. siRNA was used to disturb the expression of ZEB1-AS1. CCK-8 assay, clone formation assay and Transwell assay were used to detect the proliferation, cloning ability and migration of breast cancer MCF-7 cells in control group, siRNA-1 group and siRNA-2 group. Results The expression level of ZEB1-AS1 in breast cancer tissues was higher than that in corresponding normal tissues [M(QR): 0.001 6 (0.005 1) vs. 0.000 9 (0.001 5);Z=-4.426, P<0.001]. The higher expression of ZEB1-AS1 was correlated with lymphatic metastasis (χ2=9.148, P=0.027), negative human epidermal growth factor receptor 2 (χ2=5.039, P=0.025), triple negative breast cancer (χ2=4.597, P=0.032). The patients with the higher expression of ZEB1-AS1 had a shorter overall survival time compared with the patients with the lower expression of ZEB1-AS1 (χ2=14.340, P<0.001). CCK-8 assay showed that knock down of ZEB1-AS1 after 72 h, the absorbance values of the control group, siRNA-1 group and siRNA-2 group were 0.605±0.049, 0.488±0.054, 0.417±0.038 respectively, with a statistically significant different (F=15.936, P<0.001), and the two siRNA groups were significantly inhibited in cell proliferation compared with the control group (both P<0.05). The colonies of the control group, siRNA-1 group and siRNA-2 group were 297.5±11.4, 192.0±12.1, 204.8±12.8 respectively, with a statistically significant different (F=112.526, P<0.001), and the two siRNA groups were significantly inhibited in the cell clone compared

关 键 词：乳腺肿瘤 预后 ZEB1-AS1 

分 类 号：R737.9[医药卫生—肿瘤]